Amedeo Smart

Free Medical Literature Service



Bacterial Infections and Mycoses

  Free Subscription

Articles published in
    March 2024
    SER-109 (VOWST()): A Review in the Prevention of Recurrent Clostridioides difficile Infection.
    Drugs. 2024;84:329-336.
    >> Share

    Vonoprazan: A Review in Helicobacter pylori Infection.
    Drugs. 2024;84:319-327.
    >> Share

    September 2023
  3. KEAM SJ
    Sulbactam/Durlobactam: First Approval.
    Drugs. 2023;83:1245-1252.
    >> Share

    July 2023
  4. VENUTI F, Trunfio M, Martson AG, Lipani F, et al
    Extended and Continuous Infusion of Novel Protected beta-Lactam Antibiotics: A Narrative Review.
    Drugs. 2023;83:967-983.
    >> Share

    June 2023
  5. SYED YY
    Rezafungin: First Approval.
    Drugs. 2023;83:833-840.
    >> Share

    May 2023
  6. KANG C
    Keverprazan Hydrochloride: First Approval.
    Drugs. 2023;83:639-643.
    >> Share

    February 2023
  7. GONZALES-LUNA AJ, Carlson TJ, Garey KW
    Emerging Options for the Prevention and Management of Clostridioides difficile Infection.
    Drugs. 2023;83:105-116.
    >> Share

    December 2022
  8. EDWARDS BD, Field SK
    The Struggle to End a Millennia-Long Pandemic: Novel Candidate and Repurposed Drugs for the Treatment of Tuberculosis.
    Drugs. 2022;82:1695-1715.
    >> Share

    October 2022
  9. KHANNA S, Assi M, Lee C, Yoho D, et al
    Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection.
    Drugs. 2022;82:1527-1538.
    >> Share

    August 2022
  10. NGAN NTT, Flower B, Day JN
    Treatment of Cryptococcal Meningitis: How Have We Got Here and Where are We Going?
    Drugs. 2022;82:1237-1249.
    >> Share

    June 2022
    20-Valent Pneumococcal Conjugate Vaccine: A Review of Its Use in Adults.
    Drugs. 2022;82:989-999.
    >> Share

  12. HOY SM
    Oteseconazole: First Approval.
    Drugs. 2022;82:1017-1023.
    >> Share

    March 2022
  13. CHOU A, Welch E, Hunter A, Trautner BW, et al
    Antimicrobial Treatment Options for Difficult-to-Treat Resistant Gram-Negative Bacteria Causing Cystitis, Pyelonephritis, and Prostatitis: A Narrative Review.
    Drugs. 2022;82:407-438.
    >> Share

    December 2021
  14. REYNOLDS D, Kollef M
    The Epidemiology and Pathogenesis and Treatment of Pseudomonas aeruginosa Infections: An Update.
    Drugs. 2021;81:2117-2131.
    >> Share

    October 2021
  15. HOENIGL M, Sprute R, Egger M, Arastehfar A, et al
    The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin.
    Drugs. 2021;81:1703-1729.
    >> Share

    September 2021
  16. SYED YY
    Cefiderocol: A Review in Serious Gram-Negative Bacterial Infections.
    Drugs. 2021;81:1559-1571.
    >> Share

  17. HOY SM
    Contezolid: First Approval.
    Drugs. 2021;81:1587-1591.
    >> Share

    August 2021
  18. LEE A
    Ibrexafungerp: First Approval.
    Drugs. 2021;81:1445-1450.
    >> Share

  19. AARTS P, Dudink K, Vossen ARJV, van Straalen KR, et al
    Clinical Implementation of Biologics and Small Molecules in the Treatment of Hidradenitis Suppurativa.
    Drugs. 2021;81:1397-1410.
    >> Share

    July 2021
  20. LIN EY, Adamson PC, Klausner JD
    Epidemiology, Treatments, and Vaccine Development for Antimicrobial-Resistant Neisseria gonorrhoeae: Current Strategies and Future Directions.
    Drugs. 2021;81:1153-1169.
    >> Share

    February 2021
  21. ZHANEL GG, Deng C, Zelenitsky S, Lawrence CK, et al
    Lefamulin: A Novel Oral and Intravenous Pleuromutilin for the Treatment of Community-Acquired Bacterial Pneumonia.
    Drugs. 2021;81:233-256.
    >> Share

  22. HEO YA
    Imipenem/Cilastatin/Relebactam: A Review in Gram-Negative Bacterial Infections.
    Drugs. 2021;81:377-388.
    >> Share

Free Medical Abstracts
Privacy Policy

© Amedeo 1997-2016